BM 27

Drug Profile

BM 27

Latest Information Update: 05 Sep 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source
  • Class Neuroprotectants; Small molecules; Sulfonylureas
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Brain oedema; Stroke

Most Recent Events

  • 10 Nov 1999 A study has been added to the pharmacodynamics section
  • 05 Nov 1997 Preclinical development for Brain oedema in Belgium (Unknown route)
  • 17 Feb 1997 Preclinical development for Stroke in Belgium (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top